Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 301 - 350 out of 126,730

Document Document Title
WO/2017/152857A1
Disclosed in the present invention are an indoleamine-2,3-dioxygenase inhibitor and a preparation method therefor. The structure of the inhibitor of the present invention is shown in general formula (I), wherein the definitions of X, R1,...  
WO/2017/152655A1
Provided is a traditional Chinese medicine preparation for treating qi and blood deficiency-type generalized anxiety disorder. The medicinal raw materials thereof comprise spina date seed, angelica sinensis, radix paeoniae alba, radix re...  
WO/2017/153601A1
The present invention relates to the compounds of formula (I) that can be employed in the diagnosis, monitoring of disease progression or monitoring of drug activity, of a group of disorders and abnormalities associated with alpha-synucl...  
WO/2017/153829A1
The invention relates to a saffron extract comprising crocins and crocetins, for use in the treatment of sleep disorders in humans. According to the invention, the saffron extract comprises at least 2% by weight of crocins relative to th...  
WO/2017/153956A1
The invention provides pharmaceutical compositions comprising human immature dental pulp stem cells (hIDPSCs) wherein the hIDPSCs express CD44 and CD13. The invention also provides methods of treating a neurological disease or condition ...  
WO/2017/153834A1
Provided herein are methods of treating a CDKL5 deficiency with tideglusib or a derivative thereof.  
WO/2017/155050A1
Provided is a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity. A compound represented by formula (I) [wherein each symbol is as defined in the description] or a salt thereof has a cholinergic m...  
WO/2017/154675A1
The agent for treating Fabry disease, analgesic for external use and perspiration accelerator according to one embodiment of the present invention comprise rapamycin or a rapamycin derivative.  
WO/2017/153957A1
The invention provides a method of producing human immature dental pulp stem cells (hIDPSCs) expressing CD44 and CD13 and lacking expression of CD146. The invention also provides compositions for use in the treatment of a neurological di...  
WO/2017/154865A1
The present invention provides an ameliorating agent for a female-specific physical and/or mental unpleasant symptom, which comprises γ-tocopherol and/or equol.  
WO/2017/153459A1
The invention relates to a compound of Formula (I), or pharmaceutically acceptable enantiomers, or salts thereof. The present invention also relates to the use of compounds of Formula (I) as selective inhibitors of indoleamine 2,3-dioxyg...  
WO/2017/154822A1
Provided is a sustained release sheet that includes a drug for treating nerve damage, wherein the sheet is applied to a nerve damage site, can maintain a high concentration of the drug over a long period, and promotes nerve regeneration ...  
WO/2017/155386A1
The invention pertains to the use of therapeutically effective amounts of (i) one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof; and(ii) at least one of docosahexaenoic acid (22:6; DHA), eicosa...  
WO/2017/156242A1
The present embodiments provide methods, compounds, and compositions useful for inhibiting PMP22 expression and for treating, preventing, or ameliorating a disease associated with PMP22.  
WO/2017/155387A1
The invention pertains to the use of therapeutically effective amounts of (a) (i) vitamin C and/or selenium and (ii) at least one of docosahexaenoic acid (22:6; DHA), eicosapentaenoic acid (20:5; EPA) and docosapentaenoic acid (22:5; DPA...  
WO/2017/148878A1
The present invention provides a compound of formula (I) having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compound of the pres...  
WO/2017/151376A1
The present invention provides N-[1-(1-Cyclohexyl-3,5-dimethyl-1H-pyrazole-4-sulfonyl)-4-ph enyl-piperidin-4-ylmethyl]-N-isobutyl-4-{[(piperidin-4-ylmet hyl)-amino]-methyl}-benzenesulfonamide and pharmaceutically acceptable salts thereof...  
WO/2017/148455A1
The invention relates to iodinated aromatic choline analogs of general formula wherein at least one R is iodine; the quaternary ammonium group comprises a hydroxyl substituent, and further substituent are as defined in the claims. The co...  
WO/2017/148414A1
Provided are fucoidan, a preparation method therefor, and uses thereof. The molecular weight of the fucoidan is 100 kDa to 300 kDa, and the fucoidan mainly comprises mannose, fucose and other monosaccharide units. Also provided are a fuc...  
WO/2017/148595A1
The invention relates to Cebranopadol for use in the treatment of pain, wherein Cebranopadol is administered according to an administration regimen comprising (i) a first administration interval, which lasts for at least 2 consecutive da...  
WO/2017/149392A1
Disclosed are stable self-emulsifying compositions comprising at least one CB2 receptor modulator, a self-emulsifying vehicle and optionally at least one antipsychotic agent for use in the treatment of mental disorders, methods of prepar...  
WO/2017/149503A1
Human mutated form of NGF comprising two mutations, a first mutation being represented by the substitution of the proline amino acid in position 61 with a serine, a second mutation being represented by the substitution of an amino acid i...  
WO/2017/148406A1
The present invention relates to compounds (I) capable of inhibiting the Mst1/2 protein kinase activity, a preparation method therefor, a pharmaceutical composition comprising the compounds, and uses of the compounds and the pharmaceutic...  
WO/2017/151687A1
Compositions and methods for reducing the level of prions in a prion-infected cells or host by exposing prion infected cells, tissues and organs to AR-12 and the AR-12 analog AR-14 to reduce the prion level by at least about 90%.  
WO/2017/149469A1
Present invention relates to novel heterocyclic compounds as indoleamine 2,3- dioxygenase (IDO) and/or tryptophan 2,3-dioxygenase (TDO) modulators. Compounds of the present invention inhibit tryptophan degradation by modulating IDO and/o...  
WO/2017/150477A1
The purpose of the present invention is to provide a compound having an excellent JAK1-inhibiting activity. The compound according to the present invention has a JAK1-inhibiting activity, and therefore has an immunesuppressing effect, an...  
WO/2017/151006A1
The group of inventions relates to medicine and pharmacology, and more particularly to psychiatry, and can be used for the effective and safe treatment of psychiatric disorders associated with dysfunction in the dopamine and serotonin ne...  
WO/2017/151644A1
The present disclosure relates to oligonucleotide decoys, pharmaceutical compositions thereof, and the use of such to modulate nociceptive signaling and to prevent and/or treat pain.  
WO/2017/150228A1
The present invention addresses the problem of providing an efficacious means against muscle atrophy. Provided is a muscle atrophy inhibitor that comprises, as active ingredient(s): (1) one or more proteins selected from the group consis...  
WO/2017/151980A1
Disclosed are compositions and methods for mitigating a tolerance effect from ingestion of cannabis-based medicines in human subjects, for example, subjects having an increased risk of unresponsiveness to one or more therapeutic agents s...  
WO/2017/149333A1
The invention relates to C-3 substituted kynurenic acid derivatives with the general formula (I) wherein R1 is C1-7alkyl-, R6R7N-C1-7alkyl-, C6-10aryl-C1-7alkyl group; R2 is H or C1-7alkyl group; or R1 and R2 with the nitrogen atom to wh...  
WO/2017/149534A1
The present disclosure generally relates to nicotine formulations, nebulizer systems comprising same and uses thereof via inhalation.  
WO/2017/150704A1
An aquaporin 4 function promoter contains, as an active ingredient, a compound represented by general formula (1) or (2) or a pharmacologically acceptable salt thereof. (In the formulas, n11 is an integer of 1-10. R21 is a C1-10 alkyl gr...  
WO/2017/147654A1
The present invention relates to a method of treating or preventing a neurological condition mediated by a tau-dependent signalling complex in neurons of a subject, comprising treating the subject to: (a) promote phosphorylation of one o...  
WO/2017/147719A1
A method of treating a neuropathy, such as a recessive neuronopathy or peripheral neuropathy, in a mammal is provided. The method comprises administering to the mammal a therapeutically effective amount of exosomes genetically engineered...  
WO/2017/150475A1
[Problem] To develop a brain health food/brain health beverage for preventing/alleviating brain atrophy due to alcohol intake. [Solution] A brain health food or brain health beverage containing, as active ingredients, folic acid, vitamin...  
WO/2017/147720A1
A method of treating a central nervous system disorder in a mammal is provided. The method comprises administering to the mammal a therapeutically effective amount of non-naturally occurring exosomes engineered to comprise nucleic acid e...  
WO/2017/149339A1
The present invention relates to compounds of formula (I), which are blocked in C3 position and cannot metabolize in vivo into pregnenolone derivatives and which do not have significant affinity for steroid hormonal receptors and for all...  
WO/2017/150686A1
The present invention provides a composition that is effective in improving the symptoms of autism spectrum disorder. The composition is characterized in containing, as an active ingredient, at least one type of pyridoxamine compound sel...  
WO/2017/150327A1
The present invention addresses the problem of providing a food material that is added to food to promote in-brain secretion of neurotrophins including BDNF, and that can endow the food with a brain function improvement function and a cr...  
WO/2017/148960A1
The present invention relates to compositions for use in the treatment of neurological disease. In one embodiment, the present invention relates to a peptide analogue of xenin or gastric inhibitory polypeptide for use in the treatment of...  
WO/2017/150566A1
The present invention provides a model animal for establishing an effective treatment for protein aggregate diseases typified by Alzheimer's disease and the like. More specifically, the present invention provides the following. (A) A non...  
WO/2017/149387A1
Disclosed are stable compositions comprising at least one CB2 receptor selective or highly selective agonist and optionally at least one antipsychotic for use in the treatment of mental disorders, methods of preparing such compositions a...  
WO/2017/147285A9
The present invention is directed to a sustained release buprenorphine microsphere (SRBM) formulation capable of delivering buprenorphine, a metabolite, or a prodrug thereof for a duration of about 7 days to about 6 months.  
WO/2017/147147A1
Provided herein are compositions for treating acute, chronic, or post-operative pain in a subject, said compositions comprising a Nav1.7 selective inhibitor and a biodegradable carrier, wherein the agent is incorporated within the biodeg...  
WO/2017/147285A1
The present invention is directed to a sustained release buprenorphine microsphere (SRBM) formulation capable of delivering buprenorphine, a metabolite, or a prodrug thereof for a duration of about 7 days to about 6 months.  
WO/2017/147536A1
Compositions and methods disclosed concern an isogenic population of in vitro human embryonic stem cells comprising a disease form of the Huntingtin gene (HTT) at the endogenous HTT gene locus in the genome of the cell; wherein the disea...  
WO/2017/143990A1
The present invention provides a method for preparing a pyrrolopyrimidine compound and application thereof. Specifically, the present invention provides a compound represented by formula I or pharmaceutically-acceptable salts thereof, a ...  
WO/2017/146230A1
The purpose of the present invention is to provide an extract from inflammatory tissue inoculated with vaccinia virus, a test method using a novel method of administration of a formulation containing the extract, and the like. With the p...  
WO/2017/147529A1
The present invention relates to methods of treating neurodegenerative disorders associated with Alzheimer's disease (AD), Parkinson's disease (PD) and synucleinopathies, such as dementia with Lewy bodies, Down Syndrome (DS) and associat...  

Matches 301 - 350 out of 126,730